General Information
Revision date
2021-04-09
Product name
Progesterone Formulation
CAS No.
57-83-0
1.2.1 Relevant identified uses
Pharmaceutical
Emergency telephone
215-631-6999
Icons in SDS
Company Information
company name
Organon & Co
e-mail address of the competent person responsible for the Safety Data Sheet
EHSSTEWARD@organon.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H351, H360, H362
Hazard statements
Code
Statements
H351
Suspected of causing cancer
Section 2
CLP CLASSIFICATION
Carcinogenicity, Category 2 H351: Suspected of causing cancer. Reproductive toxicity, Category 1A H360: May damage fertility or the unborn child. Effects on or via lactation H362: May cause harm to breast-fed children.
2.2 Label elements
REGULATION (EC) No 1272/2008)
Signal word
Danger
Hazard statements
H351 Suspected of causing cancer. H360 May damage fertility or the unborn child. H362 May cause harm to breast-fed children.
Prevention
P201 Obtain special instructions before use. P260 Do not breathe dust. P263 Avoid contact during pregnancy and while nursing. P264 Wash skin thoroughly after handling. P280 Wear protective gloves/ protective clothing/ eye protec- tion/ face protection.
Response
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Hazardous Ingredients
Progesterone
Additional information
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 27.777 %
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosible dust-air mixture if dispersed.
